Exelixis and Ipsen Announce Positive CHMP Opinion for Cabometyx in Previously Treated...

[cafead]

via

• Exelixis is eligible to receive a milestone payment of $40 million for the approval of the second-line treatment of HCC
• In May of 2018, the FDA accepted for filiing an sNDA for Cabometyx for previously treated advanced HCC
• A Prescription Drug User Fee Act (PDUFA) action date of January 14 was assigned

article source